irasia.com - Novogen Limited

Novogen Limited

Board and Senior Management Team

The Board of Directors

Mr Ian Phillips MNZM (Non-Executive Director, Interim Chairman) [Appointed on 1 July 2015]
Mr Iain Ross (Director and Acting CEO) [Appointed on 22 July 2015]
Mr John P O'Connor BEC., MAICD (Non-Executive Director, Deputy Chairman)
Mr Steven Coffey CA (Non-Executive Director)
Professor Peter Gunning B.SC, PH.D (Non-Executive Director) [Effective on 3 March 2014]
Mr Bryce Carmine B.SC (Non-Executive Director) [Appointed on 3 June 2015]

Dr Graham Kelly BSC, BVSC, PHD (Executive Director, CEO) [Resigned on 22 July 2015]
Dr Andrew Heaton BSC, PHD (Executive Director) [Stepped down on 4 March 2014]
Robert Birch (Non-Executive Director, Deputy Chairman) [Stepped down on 4 March 2014]

Senior Management Team

Mr Iain Ross (Director and Acting CEO) [Appointed on 22 July 2015]
Dr Andrew Heaton BSC, PHD (Vice-President, Drug Discovery)
Dr David Brown DIP TECH MGMT, B APP SC, PHD (Chief Scientific Officer)
Ms Cristyn Humphreys BBUS(ACC), DIPPOL, FTI, CA (Chief Operating Officer (Administration and Finance))
Dr Justine Stehn BSC, PHD (ATM Program Director) [Appointed on 3 February 2014]
Dr Stephen Palmer BSC, PHD (Degenerative Diseases Program Director)
Dr Kimberley Lilischkis BSC, PHD, MBA (Clinical & Regulatory Affairs Manager)
Mr Lionel Mateo BCL MCL (Company Secretary)
Ms Kym Robins (Marketing and Communications Manager)

Dr Graham Kelly BSC, BVSC, PHD (Executive Director & CEO) [Resigned on 22 July 2015]

The Board of Directors

Mr Ian Phillips, MNZM, Non-Executive Director & Interim Chairman [Appointed on 1 July 2015]

Ian M Phillips, MNZM, has been involved with International Banking, global financial markets and Corporate Finance for over 30 years having worked in New York (20 years), London (5 years), Singapore (6 months), Sydney (5 years) and Wellington, NZ (4 years).
Ian is President of KUMARA Inc, Chairman of Nutraceutical and Natural Products AG, Deputy Chairman of the American Australian Association, Immediate Past-President of the American Friends of the National Gallery of Australia, Chairman of American New Zealand Association, an Advisory Board of the US-NZ Council, and a Board member of the American Friends of Christchurch.
Phillips studied at Otago University, University of Colorado and the London School of Economics.
Phillips holds dual USA & New Zealand citizenship.

Mr Iain Ross, Director and Acting CEO [Appointed on 22 July 2015]

Mr Ross is currently Chairman of Premier Veterinary Group PLC (formerly Ark Therapeutics PLC), a non-executive director of Amarantus Bioscience Holdings Inc and a non-executive director for ASX-listed companies Anatara Lifesciences Ltd, Benitec Biopharma Ltd and Tissue Therapies Ltd.
Following a career with multinational companies, Sandoz AG, Hoffman La Roche and Celltech Group plc, Mr Ross has over the past 20 years undertaken a number of company start-ups, turnarounds and exits as a Board member on behalf of private equity groups and banks. These include Quadrant Healthcare PLC (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia AB (sold to Cinven); SR Pharma PLC (merged with Atugen AG to form Silence Therapeutics PLC) Allergy Therapeutics Limited (prepared for IPO); and Ark Therapeutics PLC (subsidiaries sold off to private equity and a new business reversed in to form Premier Veterinary Group PLC).
Mr Ross brings to this role an impressive track record which includes multiple financing transactions, having raised more than £250m, both publicly and privately, as well as extensive experience in divestments and strategic restructures and more than 20 years in cross border management as a Chairman and CEO. He has led and participated in five IPOs on the London and Australian Stock Exchanges and two up-listings to NASDAQ, and has direct experience of M&A transactions in Europe, the US and Pacific Rim. He is a qualified Chartered Director and Vice Chairman of the Council of Royal Holloway, London University.

Mr John P O'Connor BEC., MAICD, Non-Executive Director, Deputy Chairman

Mr John O'Connor has over 30 year's experience in the financial industry and was appointed to the Novogen board in May 2012. He has held numerous management roles as a fund manager and stockbroker in the UK, US and Australia and also a partnership in a securities business. He has been a consultant to several biotech companies, including Novogen Limited and Marshall Edwards Inc., assisting with fundraising.
Mr O'Connor served on the Board of Lonsec Securities, a Zurich Insurance owned business, for several years.

Mr Steven Coffey CA, Non-Executive Director

Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.
Mr Coffey is a registered company auditor and audits a number of large private companies as well as not for profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of private family foundation.

Professor Peter Gunning B.SC, PH.D, Non-Executive Director [Effective on 3 March 2014]

Professor Peter Gunning is the Head of the Oncology Research Unit in the School of Medical Sciences and Associate Dean (Research) in the Faculty of Medicine at the University of New South Wales. His research is focused on the development of new therapeutic strategies for the treatment of childhood cancer. These strategies target the skeleton of the cancer cell and build on the principles of cell architecture that Professor Gunning's group has discovered over the last 20 years.
Professor Gunning has published over 100 primary research articles and has recently edited the first book devoted to his field of research.
Previous appointments have included leadership roles as Chair of the Division of Research at The Children's Hospital at Westmead, Chair of the Westmead Research Hub Executive and Chair, Board of Bio-Link, a company established by the NSW Government to support commercialisation of biomedical intellectual property.

Mr Bryce Carmine B.SC, Non-Executive Director [Appointed on 3 June 2015]

Bryce Carmine retired from Eli Lilly & Co. as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines business unit, which he assumed on Nov. 2009. Prior to the creation of Business Units at Lilly he had been EVP, Global Marketing and Sales and a member of the company’s Executive Committee.
In 1999 when Carmine returned to the US from Japan he held a series of portfolio leadership roles culminating in Mar. 2005 when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Lilly.
During his career with Lilly Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. Born in New Zealand, he received a B.Sc. in biochemistry from Massey University prior to joining Eli Lilly in NZ.
Bryce is currently Chairman & CEO for HaemaLogiX, a newly formed Sydney-based biotechnology company.

Senior Management Team

Mr Iain Ross, Director and Acting CEO [Appointed on 22 July 2015]

Dr Andrew Heaton BSC, PHD, Vice-President, Drug Discovery

Dr Heaton has extensive drug discovery background. He studied the complex interactions of signalling molecules associated with the mass spawning phenomena on the Great Barrier Reef. Following completion of his Ph.D studies he completed post-doctoral research discovering molecules with unique biological activity from marine environment.
Dr Heaton first joined Novogen in 1998 as General Manager of the drug discovery program; progressing 4 compounds to clinical trials. He was responsible for the design and execution of the Novogen drug.

Dr David Brown DIP TECH MGMT, B APP SC, PHD, Chief Scientific Officer

Dr. David Brown joined Novogen in 2000 and championed the pre-clinical and translational development of Phenoxodiol, Triphendiol, ME-128, ME-143 and ME-344. In 2010, Dr Brown left Novogen and worked as a Medical Advisor for Janssen as part of the Regional Immunology group. Dr Brown is a co-founder of Triaxial Pharmaceuticals and as a result of Novogen's acquisition of Triaxial re-joined Novogen in 2013 as the company's Group Chief Scientific Officer where he currently oversees all scientific operations both locally and internationally with our commercial and academic partners. Dr Brown currently sits on the CanTx Board of Directors, Novogen's joint venture company with Yale University.
Dr Brown has over 20 years' experience in all non-clinical aspect of drug discovery and development. He holds a PhD from the University of Queensland, and has held several research appointments at the Queensland Institute of Medical Research (University of Queensland) and University of New South Wales. Dr Brown has co-authored 10 patents, several IND applications, and over 30 peer-reviewed scientific articles.

Ms Cristyn Humphreys BBUS(ACC), DIPPOL, FTI, CA, Chief Operating Officer (Administration and Finance)

Cristyn has 20 years commercial experience working for private industries including heading up finance, marketing and strategy departments for businesses with a global presence. Cristyn's commercial experience is broad including founding a registered charity in Australia and working in the NSW Police Service. She is a Chartered Accountant and a Fellow of the Tax Institute in Australia.

Dr Justine Stehn BSC, PHD, ATM Program Director [Appointed on 3 February 2014]

Dr Stehn joined Novogen in February 2014 and is responsible for the drug development of the ATM program, which was acquired by Novogen in 2013 and Dr Stehn is also the co-inventor. Dr Stehn has over 20 years research experience in understanding the role of the cell cytoskeleton in disease. After receiving her PhD from the Garvan Institute of Medical Research, Sydney, Justine was awarded a prestigious National Health and Medical Research Council (NHMRC), CJ Martin Fellowship to support her post doctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT), Boston, USA.
Upon returning to Australia, Justine headed up the Anti-tropomyosin (ATM) drug development program at UNSW Australia. She has been involved in the ATM program since its inception in 2007 and has been instrumental in driving the preclinical development of the ATM compounds for the treatment of cancer.

Dr Stephen Palmer BSC, PHD, Degenerative Diseases Program Director

Dr Palmer joined Novogen in 2014 and is responsible for running the drug discovery programme centred around stimulating regenerative processes in stem cells and developing novel therapies for degenerative diseases including dementia, muscular dystrophy, lysosomal storage disorders and autoimmune disease.
Dr Palmer completed his PhD in 1992 at University College London and established a career studying the genetic regulation of embryonic development and inherited disorders. Using genetically modified mice as models of human disease, he has studied normal and abnormal cellular function in several different organ systems.
Dr Palmer migrated to Australia on a Wellcome Trust International Travelling Fellowship and worked at the Victor Chang Cardiac Research Institute and the Children's Medical Research Institute in Sydney. He established a research program on the neurodevelopmental disorder Williams-Beuren syndrome, demonstrating the key role of the GTF2IRD1 protein. He currently holds a conjoint Senior Lectureship at UNSW Australia.

Dr Kimberley Lilischkis BSC, PHD, MBA, Clinical & Regulatory Affairs Manager

Kimberley is a Clinical Research and Regulatory Manager with extensive scientific research training. She has clinical trials management knowledge and experience in both the academic research environment and industry. Her scientific research career spans more than 20 years in both clinical and laboratory research areas in Australia and Europe. Kimberley has a focused interest in oncology research and the translation of new findings into improved health outcomes for cancer patients.

Lionel Mateo BCL MCL, Novogen Group, Company Secretary

Lionel is our resident European on the Novogen team. Growing up in the south of France, Lionel has a Bachelor's degree in Civil Law and a Master's Degree in Civil Law, Economics and Business from the University of Aix en Provence, France.
Lionel originally had a passion for Criminal Law, but after deciding to settle in Australia, he chose to specialise in corporate governance. Having worked previously for R.M.Williams Agricultural Holdings, first as corporate governance officer, he was then appointed Company Secretary.
In late 2013 he joined Novogen as Group Company Secretary and is currently completing the Graduate Diploma in Applied Corporate Governance with the Governance Institute of Australia.

updated 22nd July, 2015

Company's Index

irasia.com

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited.
TERMS OF USE: Please read the Terms of Use governing the use of our website.